Experimental and theoretical study of the {sup 2}H(d-vector{gamma}){sup 4}He reaction below E{sub c.m.}=60 keV von Sabourov, K., Ahmed, M.W., Canon, S.R., Crowley, B., Joshi, K., Kelley, J.H., Nelson, S.O., Perdue, B.A., Schreiber, E.C., Sabourov, A., Tonchev, A., Weller, H.R., Wulf, E.A., Prior, R.M., Spraker, M.C., Hofmann, H.M., Trini, M., Triangle Universities Nuclear Laboratory, Box 90308, Durham, North Carolina 27708, Department of Physics, North Georgia College and State University, Dahlonega, Georgia, 30597, Physics Department, University of Erlangen-Nuernberg, Erlangen

Volltext

201P Afatinib for EGFR, HER2 or HER3 mutated solid tumors: A phase II Belgian precision study von Decoster, L., Aftimos, P.G., Rottey, S., Prenen, H., Collignon, J.J., Mebis, J., Canon, J-L., Fastenaekels, V., Cappoen, N., Joris, S.R., De Grève, J.

Volltext

152P Efficacy of olaparib in advanced cancers with germline or somatic tumor mutations in BRCA1, BRCA2, CHEK2 and ATM: A Belgian precision tumor-agnostic phase II study von Joris, S.R., Denys, H., Collignon, J.J., Rasschaert, M., T'Kint de Roodenbeke, D., Duhoux, F.P., Canon, J-L., Tejpar, S., Mebis, J., Decoster, L., Aftimos, P.G., De Grève, J.

Volltext

Efficacy of olaparib in advanced cancers with germline or somatic tumor mutations in BRCA1, BRCA2, CHEK2 and ATM: A Belgian precision tumor-agnostic phase II study von Joris, S.R, Denys, H, Collignon, J.J, Rasschaert, M, de Roodenbeke, D. T'Kint, Duhoux, F.P, Canon, J.-L, Tejpar, S, Mebis, J, Decoster, L, Aftimos, P.G, De Greve, J

Volltext